Kodiak Sciences reports Q2 EPS ($1.03), consensus ($1.05)

Ended Q2 with $104.2M of cash and cash equivalents, believes current cash will support current and planned operations into 2026. “Our July 16 Investor R&D Day brought forward compelling new data along with a clear commercial vision for our three late-stage clinical assets -tarcocimab, KSI-501 and KSI-101- underscoring their transformative potential in retinal disease treatment,” said CEO Victor Perlroth. “The event featured new 12-week data from the KSI-101 APEX Phase 1b study, underscoring the opportunity for KSI-101 to treat patients with macular edema secondary to inflammation (MESI). The webcast also offered scientific, clinical and commercial perspectives and included commentary from two retina opinion leaders Dr. Sumit Sharma and Dr. Charles Wykoff. We encourage you to listen to the webcast and to review the presentation which are both available on the Investors & Media page of our website.”